Psychometric Properties of IntelliSpace Cognition

Philips

Status: Completed

Conditions: Cognitive Functioning of Healthy Individuals

Treatments: Device: IntelliSpace Cognition (ISC); Diagnostic Test: Paper-Pencil Tests

Study type: Interventional

Funder types: Industry; Other

Identifiers

NCT03801382

ICBE-2-28674

Details and patient eligibility

About

This study aims to validate the tests that are on the IntelliSpace Cognition platform and to establish normative data for these tests.

Enrollment: 450 patients

Sex: All

Ages: 50 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Examinee's primary language (language most often spoken) must be English.
• If examinee has vision impairment or hearing loss, must be corrected to normal.
• Must have normal fine and gross motor ability
• Must have use of fingers, hands, and arms to be able to use a pencil to write symbols.
• Must be able to understand subtest instructions and participate fully in testing.

Exclusion criteria

• Evidence of current cognitive impairment.
• Disruptive behavior or insufficient compliance with testing to ensure a valid assessment.
• Examinee must not be currently admitted to a hospital, assisted living, nursing home or a psychiatric facility.
• Examinee must not be diagnosed with a neurological disorder or disease (e.g., Parkinson's, brain tumor, stroke, TBI, epilepsy [if # seizures ≤ 2 and not receiving ongoing treatment for seizures, and not currently seeking medical evaluation or attention related to seizures, examinee can be accepted], encephalitis, dementia, language disorder (expressive or mixed receptive/expressive excluded; articulation disorder is ok), learning disorder.
• Must not have been unconscious related to traumatic brain injury or "medical condition" > 20 minutes (however, e.g., heat stroke, medication induced are ok) or any head-injury resulting in an overnight hospital stay.
• Any history of a medical event requiring resuscitation in which examinee was non-responsive for > 15 minutes.
• Must not have current or recent functional change (ability to carry out usual duties at work, in school, IADLs [driving, shopping, managing money], etc.) due to cognitive change.
• Examinee must not be receiving chemotherapy treatment, or have received chemotherapy treatment in the past 2 months.
• Examinee must not have a history of ECT or radiation to the CNS.
• Examinee must not be (currently or in the past) diagnosed with a psychotic disorder, or currently diagnosed with a mood disorder (however, Major Depressive Disorder in remission or with no current episode, and Dysthymic and Adjustment Disorders, are acceptable) or an anxiety disorder with symptoms significant enough to interfere with optimal test performance.
• Autoimmune disorder (e.g., LUPUS, Multiple Sclerosis)
• Examinee must not be currently diagnosed with substance abuse or dependence, or have carried any substance abuse or dependence diagnosis in the past year (> 1 year in remission diagnoses are ok). Long term alcohol abusers are excluded as well (e.g., abused substance for more than 10 years).
• Any history of Autism Spectrum Disorder or Intellectual Disability.
• The examinee must not be currently taking medication that might impact test performance (e.g., anti-convulsants, antipsychotics, benzodiazepines, psychostimulants, opiods, tricyclic antidepressants, some norepinephrine reuptake inhibitors). Most antihypertensive medications and statins are acceptable.
• If previously diagnosed with any physical condition or illness that might depress test performance, illness must not interfere with normal cognitive functioning at work, school, ADLs, etc. Diabetes, hypothyroidism, and hypertension are acceptable if controlled.
• Exclude primarily nonverbal or uncommunicative. Must not have a diagnosis of aphasia.
• Examinees should not have received neuropsychological testing although previous MMSE testing is allowed if more than 6 months prior
• Examinee must not be seeking medical diagnostic procedures for cognitive difficulties from a medical professional.
• Non-valid health insurance in USA.

Trial design

Primary purpose: Other

Allocation: Non-Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

450 participants in 5 patient groups

Digital / Paper

Other group

Description:

Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using paper-pencil tests.

Treatment:

Diagnostic Test: Paper-Pencil Tests

Device: IntelliSpace Cognition (ISC)

Paper / Digital

Other group

Description:

Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using digital tests.

Treatment:

Diagnostic Test: Paper-Pencil Tests

Device: IntelliSpace Cognition (ISC)

Digital / Digital

Other group

Description:

Phase 1: Participants' cognition is measured using digital tests. Phase 2: Participants' cognition is measured using digital tests.

Treatment:

Device: IntelliSpace Cognition (ISC)

Paper / Paper

Other group

Description:

Phase 1: Participants' cognition is measured using paper-pencil tests. Phase 2: Participants' cognition is measured using paper-pencil tests.

Treatment:

Diagnostic Test: Paper-Pencil Tests

Digital

Other group

Description:

Phase 1: Participants' cognition is measured using digital tests. Phase 2: N/A

Treatment:

Device: IntelliSpace Cognition (ISC)